

## Conference Highlights featuring ACTC Collaborators

This itinerary lists some of the main sessions being presented at CTAD (keynotes and symposiums), as well as those where ACTC members are either presenting or have co-authored the presentation. We hope this highlights and provides insight into some of the work being done by ACTC members and collaborators.

*Sessions are listed in Eastern Standard Time (North America).  
Schedule is current at the time of posting. Titles are listed as submitted.*

### Sessions featuring ACTC Collaborators as Presenters / Co-Authors

Date and Time	Session Information
Tuesday, Oct 24 4:00pm	<b>Welcome Ceremony and CTAD Lifetime Achievement Award</b> Presented to Randall J. Bateman, MD
Tuesday, Oct 24 4:30pm	<b>Keynote 1 – Pathophysiology insights of blood tests, disease modifying treatments, and the potential for prevention of Alzheimer’s disease</b> Randall J. Bateman, <i>Washington University School of Medicine</i>
Tuesday, Oct 24 4:55pm	<b>Symposium 1 – The Effects of Race and Gender on Amyloid Positivity</b> Suzanne Schindler, Robin Wolz, Charles Windon
Tuesday, Oct 24 6:50pm	<b>CTAD Welcome Reception</b>
Wednesday, Oct 25 9:00am	<b>Keynote 2 – Creating more Equitable and Valid Alzheimer’s Clinical Trials for the 21<sup>st</sup> Century</b> Monica Rivera-Mindt, <i>Icahn School of Medicine at Mount Sinai</i>
Wednesday, Oct 25 9:25am	<b>Symposium 2 – Donanemab I Early Symptomatic Alzheimer’s Disease: Additional Insights from TRAILBLAZER-ALZ 2</b> Steve Greenberg, Mark Mintun, Alireza Atri
Wednesday, Oct 25 10:15am	<b>Group photo (meet at poster P002)</b>
Wednesday, Oct 25 12:05pm	<b>OC4 – Rapid detection of the earliest amyloid-related changes in memory consolidation: assessment of learning using daily digital testing</b> Kate Papp, Roos Jutten, Daniel Soberanes, <i>Harvard Medical School</i>
Wednesday, Oct 25 1:00pm	<b>Group lunch at TBD</b>
Wednesday, Oct 25 1:40pm	<b>Late Breaking Symposium 3 – Clinical and ATN Biomarker Findings on the Impact of Amyloid Removal in a 10 year prevention trial – the DIAN-TU-001</b> Eric McDade, Guoqiao, Randall Bateman
Wednesday, Oct 25 3:20pm	<b>Lake Breaking Roundtable 1 – NIA-AA Revised Criteria for Diagnosis and Staging of Alzheimer’s disease</b> Clifford Jack, Reisa Sperling, Oskar Hansson, Heather Snyder, Laurie Ryan

## Conference Highlights featuring ACTC Collaborators

Wednesday, Oct 25 4:20pm	<b>Keynote 3 – Alzheimer’s Disease: The Drug Development Pipeline and Emerging Therapies</b> Jeffrey Cummings, <i>University of Nevada Las Vegas</i>
Wednesday, Oct 25 4:55pm	<b>LB11 – Rapid amyloid clearance and efficacy: Results from TRAILBLAZER-ALZ 2, a phase 3 study of donanemab for treatment of early Alzheimer’s disease</b> Sergey Shcherbinin, Ming Lu, Jian Wang, <i>Eli Lilly and Company</i>
Wednesday, Oct 25 5:10pm	<b>LB12 – Reduced caregiver distress associated with neuropsychiatric symptoms in EMERGE, a Phase 3, double-blind clinical trial of aducanumab in participants with early Alzheimer’s disease</b> Jeffrey Cummings, Sharon Cohen, Jennifer Murphy
Wednesday, Oct 25 5:10pm	<b>Late Breaking Symposium 4 – Lecanemab for Early Alzheimer’s Disease: Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration</b> Chrstopher van Dyck, Keith Johnson, Reisa Sperling, Michael Irizzary
Thursday, Oct 26 7:30am	<b>Poster walkthrough (meet at poster P002)</b>
Thursday, Oct 26 11:00am	<b>Keynote 4 – Clinical Trials in Alzheimer’s Disease Prevention</b> Sandrine Andrieu, <i>Toulouse University Hospital</i>
Thursday, Oct 26 11:25am	<b>Symposium 5 – What can we LEARN from the A4 Study? Association among longitudinal cognitive, functional, biomarker and imaging outcomes</b> Roy Yaari, Keith Johnson, Reisa Sperling
Thursday, Oct 26 4:05pm	<b>OC20 – Estimating Time-Saving Treatment Effects in Alzheimer’s Clinical Trials: Exploring Alternative Approaches</b> Guoqiao Wang, Gary Cutter, Lon Schneider
Thursday, Oct 26 4:20pm	<b>OC21 – The Potential for Time Savings in Early Alzheimer Clinical Trials</b> Lon Schneider, Guoqiao Wang, Richard Kennedy
Thursday, Oct 26 5:05pm	<b>Late Breaking Symposium 6 – Implementing blood biomarkers in clinical practice and trials</b> Suzanne Schindler, Oskar Hansson, Robert Rissman
Friday, Oct 27 8:45am	<b>LB18 – CT1812 START Study Design: Anti-A<math>\beta</math> Monoclonal Antibodies as Background Therapy</b> Christopher van Dyck, Rema Raman, Michael Donohue, Robert Rissman, Michael Rafii
Friday, Oct 27 9:00am	<b>Keynote 5 – What we have learned about ARIA in anti-amyloid antibody treatment in mice and the implications for AD clinical trials</b> Cynthia A. Lemere, <i>Brigham and Women’s Hospital and Harvard Medical School</i>
Friday, Oct 27 9:25am	<b>Late Breaking Symposium 7 – INTERCEPT-AD phase 1 insights and findings from the investigation of ACU193, a monoclonal antibody targeting soluble A<math>\beta</math> oligomers</b> Mirjam Trame, Eric Siemers, Stephen Salloway
Friday, Oct 27	<b>OC24 – Alzheimer’s Disease in Down Syndrome: Clinical Trials</b>

## Conference Highlights featuring ACTC Collaborators

10:30am	Michael Rafii, <i>Alzheimer's Therapeutic Research Institute, University of Southern California</i>
Friday, Oct 27 4:15pm	<b>LB26 – Feasibility of remote blood collection and plasma biomarker analyses to assess eligibility for Alzheimer's disease preclinical clinical trials – The AlzMatch Study</b> Rema Raman, Sarah Walter, Gustavo Jimenez-Maggiora, Robert Rissman, <i>Alzheimer's Therapeutic Research Institute, University of Southern California</i>